CHICAGO (EGMN) - Allogeneic transplantation confers a significant survival advantage, particularly among younger patients, when treating Philadelphia chromosome-positive acute lymphoblastic leukemia with a regimen that adds imatinib to hyper-CVAD chemotherapy, a clinical study suggests.Among patients aged 40 years or younger with de novo disease, the 3-year overall survival rate was 90% in those who went on to allogeneic stem cell transplant, compared with 33% for those who did not undergo transplant...